Dotarizine

Dotarizine

Dotarizine is a vasodilator and calcium channel blocker that was developed for the treatment of migraine. It is a member of the diphenylmethylpiperazine group of compounds and was developed in the 1980s by the Spanish pharmaceutical company Esteve.

Pharmacology

Dotarizine acts as a calcium channel blocker, specifically blocking L-type and T-type calcium channels. This action is believed to contribute to its efficacy in treating migraine. In addition to its calcium channel blocking activity, dotarizine also acts as a vasodilator, increasing blood flow in the brain. This is thought to further contribute to its anti-migraine effects.

Clinical Use

Dotarizine has been studied for the treatment of migraine and vertigo. Clinical trials have shown it to be effective in reducing the frequency and severity of migraine attacks. It has also been found to be beneficial in the treatment of vertigo associated with Meniere's disease and other vestibular disorders.

Side Effects

The most common side effects of dotarizine are drowsiness and weight gain. Other side effects can include dry mouth, constipation, and blurred vision. As with all medications, the potential benefits of treatment with dotarizine should be weighed against the potential risks.

Availability

Dotarizine is not currently available in the United States, but it is available in some European countries.

See Also

• Calcium channel blocker
• Vasodilator
• Migraine
• Vertigo
• Meniere's disease

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

This article is a stub related to pharmacology. You can help WikiMD by expanding it!